A Phase 1 interventional study of AZD9977 oral suspension and AZD9977 placebo oral suspension in Pharmacodynamics and Healthy Subjects, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-29.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 following Single-Dose administration to healthy male subjects
This study will be a phase I study to assess the pharmacodynamics of AZD9977 following single-dose administration to healthy male subjects. It is a single-blind (with regards to AZD9977 and AZD9977 Placebo), randomized, four-treatment, four-period crossover design, with a potential 5th and 6th randomized cross-over treatment period. In this study eplerenone is used as a positive control and fludrocortisone will be used as a challenge agent. In addition the safety, tolerability and pharmacokinetics will be assessed.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Optional: Provision of signed and dated written informed consent for genetic research.
Note: Participation in exploratory biomarker research is mandatory. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.
Exclusion criteria
Abnormal findings in vital signs, after 10 minutes resting in the supine position, defined as any of the following:
Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of first dosing. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest.
Note: Subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.
In addition, any of the following is regarded as a criterion for exclusion from the genetic research:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets
Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets
Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets
Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets
Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets
Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets
Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets
Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets
AZD9977 oral suspension, single dose
oral suspension, single dose
Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977.
The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose. NOTE: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours.
Time frame: From 2 hours post dose to 8 hours post dose
Observed Maximum Concentration (Cmax) of AZD9977
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of AZD9977.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC[0-t]) of AZD9977.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Time to Reach Maximum Concentration (Tmax) of AZD9977.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Terminal Half-life (t½λz) of AZD9977.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Apparent Clearance (CL/F) of AZD9977.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Apparent Volume of Distribution at Terminal Phase (Vz/F) of AZD9977.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Apparent Volume of Distribution at Terminal Phase (Vz/F) of Eplerenone.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Apparent Clearance (CL/F) of Eplerenone.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Terminal Half-life (t½λz) of Eplerenone.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Time to Reach Maximum Concentration (Tmax) of Eplerenone.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Observed Maximum Concentration (Cmax) of Eplerenone.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC(0-t)) of Eplerenone.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of Eplerenone.
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
Time frame: From 2 hours post dose to 8 hours post dose
Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in AZD9977 Treatment With Placebo Versus Treatment With AZD9977.
The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose. NOTE: Note: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours.
Time frame: From 2 hours post dose to 8 hours post dose
Number of Participants With Clinically Significant Blood Pressure Values.
Clinically significant blood pressure values (if available) were recorded for all participants. The systolic blood pressure (mmHg) and diastolic BP (mmHg) was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol. Abnormal findings in blood pressure after 10 minutes resting in the supine position was defined as following: * Systolic blood pressure (SBP) \< 90 mmHg or ≥ 140 mmHg * Diastolic blood pressure (DBP) \< 50 mmHg or ≥ 90 mmHg.
Time frame: From screening to post-study visit, up to 10 weeks
Number of Participants With Clinically Significant Pulse Rate.
Clinically significant pulse rate (if available) was recorded for all participants in the study. The pulse was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol. Abnormal findings in pulse rate, after 10 minutes resting in the supine position, was defined as following: • Pulse \< 45 or \> 85 beats per minute (bpm)
Time frame: From screening to post-study visit, up to 10 weeks
Number of Participants With Clinically Significant Electrocardiogram.
Clinically significant electrocardiogram values were recorded for all participants in the study. A 12-lead ECG was obtained after each subject had rested in the supine position for at least 10 minutes and was performed in accordance with the Schedule of Assessments of study protocol. The investigator judged the overall interpretation as normal or abnormal. If abnormal, it would have been decided as to whether or not the abnormality was clinically significant and the reason for the abnormality would have been recorded. The investigator could add extra 12-lead resting ECG safety assessments if there were any abnormal findings of if the investigator considered it was necessary for any other safety reason. These assessments would have been entered as an unscheduled assessment.
Time frame: From screening to post-study visit, up to 10 weeks
Number of Participants With Clinically Significant Physical Examination Values.
Number of participants with clinically significant physical examination values. The complete physical examinations included an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, mouth and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. The brief physical examinations included an assessment of the general appearance, skin, abdomen, cardiovascular and respiratory systems. The results of the physical examination were listed by body system for each subject. Body weight was listed by participant and time-point. Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment were reported as an adverse event (AE).
Time frame: From screening to post-study visit, up to 10 weeks
Number of Participants With Clinically Significant Safety Laboratory Tests Values.
Clinically significant safety laboratory test values included hematology, clinical chemistry, urinalysis and urine chemistry, including urine creatinine and uric acid measurements. Viral serology and urine drugs of abuse, alcohol and cotinine were assessed for eligibility. If deterioration in laboratory value was associated with clinical symptoms and/or signs, the symptom or sign were reported as an adverse event and the associated laboratory result was considered as additional information. Laboratory results were listed and summarized according to change from baseline and repeat/unscheduled measurements. Any out of range laboratory results were flagged in the individual listings.
Time frame: From screening to post-study visit, up to 10 weeks
Pharmacodynamics of AZD9977 Assessed by Estimating the Fractional Sodium Excretion in Urine for Each Urine Collection Time Interval.
Pharmacodynamics of AZD9977 by assessment of fractional sodium excretion in urine for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.
Time frame: From 0 to 8 hours after dosing
Pharmacodynamics of AZD9977 Assessed Per Total Sodium Excreted Cumulatively and During Each of the Urine Collection Intervals.
Pharmacodynamics of AZD9977 by assessment of total sodium excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.
Time frame: From 0 to 24 hours after dosing
Pharmacodynamics of AZD9977 Assessed Per Fractional Potassium Excretion in Urine for Each Urine Collection Time Interval.
Pharmacodynamics of AZD9977 assessed per fractional potassium excretion in urine for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone
Time frame: From 0 to 8 hours post dosing
Pharmacodynamics of AZD9977 by Assessment of Total Potassium Excreted Cumulatively and During Each of the Urine Collection Intervals
Pharmacodynamics of AZD9977 by assessment of total potassium excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone in comparison to AZD9977 placebo.
Time frame: From 0 to 24 hours after dosing
Pharmacodynamics of AZD9977 Assessed Per Urine Production for Each Urine Collection Time Interval.
Pharmacodynamics of AZD9977 assessed per urine production for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.
Time frame: From 8 hours before dosing until 24 hours after dosing
Pharmacodynamics of AZD9977 by Assessment of Total Urine Volume Excreted Cumulatively and During Each of the Urine Collection Intervals
Pharmacodynamics of AZD9977 by assessment of total urine volume excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone
Time frame: From 8 hours before dosing until 24 hours after dosing
This study was conducted at PAREXEL Early Phase Clinical Unit London, United Kingdom
| Milestone | All Particpants |
|---|---|
| Started | 23 |
| Completed | 23 |
| Not completed | 0 |
The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose. NOTE: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours.
| sodium/potassium ratio | Treatment C | Treatment D |
|---|---|---|
| Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977. | -0.545 ± 1.19 | 0.694 ± 1.18 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| nmol/L | Treatment D | Treatment B |
|---|---|---|
| Observed Maximum Concentration (Cmax) of AZD9977 | 6238 ± 16.7 | 5816 ± 22.2 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| h*nmol/L | Treatment D | Treatment B |
|---|---|---|
| Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of AZD9977. | 21060 ± 18.4 | 19120 ± 23.9 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| h*nmol/L | Treatment D | Treatment B |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC[0-t]) of AZD9977. | 19970 ± 20.3 | 18520 ± 23.6 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| h | Treatment D | Treatment B |
|---|---|---|
| Time to Reach Maximum Concentration (Tmax) of AZD9977. | 0.52 (0.48 to 1.02) | 0.50 (0.48 to 2.50) |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| h | Treatment D | Treatment B |
|---|---|---|
| Terminal Half-life (t½λz) of AZD9977. | 6.753 ± 2.322 | 6.726 ± 1.719 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| L/h | Treatment D | Treatment B |
|---|---|---|
| Apparent Clearance (CL/F) of AZD9977. | 23.78 ± 18.4 | 26.20 ± 23.9 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| L | Treatment B | Treatment D |
|---|---|---|
| Apparent Volume of Distribution at Terminal Phase (Vz/F) of AZD9977. | 246.7 ± 42.4 | 220.4 ± 34.3 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| L | Treatment C | Treatment D |
|---|---|---|
| Apparent Volume of Distribution at Terminal Phase (Vz/F) of Eplerenone. | 49.11 ± 19.2 | 44.77 ± 19.3 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| L/h | Treatment C | Treatment D |
|---|---|---|
| Apparent Clearance (CL/F) of Eplerenone. | 10.87 ± 34.4 | 9.360 ± 35.9 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| h | Treatment C | Treatment D |
|---|---|---|
| Terminal Half-life (t½λz) of Eplerenone. | 3.232 ± 0.8305 | 3.419 ± 0.8843 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| h | Treatment C | Treatment D |
|---|---|---|
| Time to Reach Maximum Concentration (Tmax) of Eplerenone. | 1.98 (0.48 to 3.98) | 2.00 (0.97 to 3.98) |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| ng/mL | Treatment C | Treatment D |
|---|---|---|
| Observed Maximum Concentration (Cmax) of Eplerenone. | 1557 ± 26.1 | 1729 ± 23.2 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| h*ng/mL | Treatment C | Treatment D |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC(0-t)) of Eplerenone. | 9035 ± 33.9 | 10510 ± 34.6 |
Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours
| h*ng/mL | Treatment C | Treatment D |
|---|---|---|
| Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of Eplerenone. | 9199 ± 34.4 | 10680 ± 35.9 |
The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose. NOTE: Note: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours.
| sodium/potassium ratio | Treatment A | Treatment B |
|---|---|---|
| Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in AZD9977 Treatment With Placebo Versus Treatment With AZD9977. | -4.09 ± 2.11 | -0.694 ± 1.27 |
Clinically significant blood pressure values (if available) were recorded for all participants. The systolic blood pressure (mmHg) and diastolic BP (mmHg) was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol. Abnormal findings in blood pressure after 10 minutes resting in the supine position was defined as following: * Systolic blood pressure (SBP) \< 90 mmHg or ≥ 140 mmHg * Diastolic blood pressure (DBP) \< 50 mmHg or ≥ 90 mmHg.
| Participants | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Blood Pressure Values. | 0 | 0 | 0 | 0 |
Clinically significant pulse rate (if available) was recorded for all participants in the study. The pulse was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol. Abnormal findings in pulse rate, after 10 minutes resting in the supine position, was defined as following: • Pulse \< 45 or \> 85 beats per minute (bpm)
| Participants | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Pulse Rate. | 0 | 0 | 0 | 0 |
Clinically significant electrocardiogram values were recorded for all participants in the study. A 12-lead ECG was obtained after each subject had rested in the supine position for at least 10 minutes and was performed in accordance with the Schedule of Assessments of study protocol. The investigator judged the overall interpretation as normal or abnormal. If abnormal, it would have been decided as to whether or not the abnormality was clinically significant and the reason for the abnormality would have been recorded. The investigator could add extra 12-lead resting ECG safety assessments if there were any abnormal findings of if the investigator considered it was necessary for any other safety reason. These assessments would have been entered as an unscheduled assessment.
| Participants | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram. | 0 | 0 | 0 | 0 |
Number of participants with clinically significant physical examination values. The complete physical examinations included an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, mouth and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. The brief physical examinations included an assessment of the general appearance, skin, abdomen, cardiovascular and respiratory systems. The results of the physical examination were listed by body system for each subject. Body weight was listed by participant and time-point. Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment were reported as an adverse event (AE).
| Participants | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Physical Examination Values. | 0 | 0 | 0 | 0 |
Clinically significant safety laboratory test values included hematology, clinical chemistry, urinalysis and urine chemistry, including urine creatinine and uric acid measurements. Viral serology and urine drugs of abuse, alcohol and cotinine were assessed for eligibility. If deterioration in laboratory value was associated with clinical symptoms and/or signs, the symptom or sign were reported as an adverse event and the associated laboratory result was considered as additional information. Laboratory results were listed and summarized according to change from baseline and repeat/unscheduled measurements. Any out of range laboratory results were flagged in the individual listings.
| Participants | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Safety Laboratory Tests Values. | 0 | 0 | 0 | 0 |
Pharmacodynamics of AZD9977 by assessment of fractional sodium excretion in urine for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.
| % value | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| 0 to 2 hours | 0.34 ± 0.18 | 0.33 ± 0.19 | 0.32 ± 0.09 | 0.33 ± 0.20 |
| 2 to 4 hours | 0.22 ± 0.15 | 0.48 ± 0.21 | 0.35 ± 0.12 | 0.37 ± 0.17 |
| 4 to 6 hours | 0.15 ± 0.12 | 0.58 ± 0.19 | 0.36 ± 0.13 | 0.38 ± 0.14 |
| 6 to 8 hours | 0.16 ± 0.15 | 0.66 ± 0.23 | 0.36 ± 0.16 | 0.48 ± 0.23 |
Pharmacodynamics of AZD9977 by assessment of total sodium excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.
| mmol | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| 0 to 2 hours | 7 ± 3 | 8 ± 6 | 7 ± 3 | 7 ± 4 |
| 2 to 4 hours | 12 ± 6 | 17 ± 7 | 15 ± 5 | 15 ± 7 |
| 4 to 6 hours | 15 ± 8 | 31 ± 12 | 23 ± 8 | 23 ± 8 |
| 6 to 8 hours | 19 ± 10 | 46 ± 14 | 32 ± 10 | 34 ± 10 |
| 8 to 10 hours | 23 ± 12 | 63 ± 17 | 39 ± 12 | 47 ± 14 |
| 10 to 12 hours | 28 ± 14 | 74 ± 19 | 46 ± 13 | 55 ± 16 |
| 12 to 14 hours | 32 ± 17 | 82 ± 22 | 51 ± 14 | 62 ± 19 |
| 14 to 16 hours | 36 ± 18 | 87 ± 23 | 54 ± 15 | 67 ± 21 |
| 16 to 24 hours | 46 ± 23 | 103 ± 29 | 66 ± 19 | 79 ± 24 |
Pharmacodynamics of AZD9977 assessed per fractional potassium excretion in urine for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone
| % value | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| 0 to 2 hours | 21.72 ± 6.49 | 22.19 ± 3.96 | 21.14 ± 5.74 | 21.66 ± 5.40 |
| 2 to 4 hours | 22.26 ± 4.22 | 20.30 ± 4.45 | 18.95 ± 2.78 | 21.15 ± 5.25 |
| 4 to 6 hours | 14.60 ± 3.19 | 12.49 ± 3.04 | 12.12 ± 3.03 | 12.48 ± 3.13 |
| 6 to 8 hours | 18.08 ± 4.64 | 13.35 ± 5.60 | 13.34 ± 4.56 | 13.48 ± 3.55 |
Pharmacodynamics of AZD9977 by assessment of total potassium excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone in comparison to AZD9977 placebo.
| mmol | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| 0 to 2 hours | 13.6 ± 5.6 | 14.5 ± 3.1 | 14.0 ± 5.8 | 13.7 ± 4.2 |
| 2 to 4 hours | 29.0 ± 9.4 | 26.7 ± 5.7 | 27.1 ± 7.7 | 27.4 ± 7.6 |
| 4 to 6 hours | 38.3 ± 11.1 | 35.2 ± 6.8 | 35.5 ± 8.8 | 35.9 ± 9.2 |
| 6 to 8 hours | 49.9 ± 13.3 | 44.4 ± 8.7 | 44.6 ± 10.4 | 45.1 ± 10.7 |
| 8 to 10 hours | 61.4 ± 14.7 | 54.4 ± 10.2 | 53.8 ± 11.0 | 54.9 ± 11.0 |
| 10 to 12 hours | 71.1 ± 15.7 | 62.1 ± 12.2 | 63.3 ± 11.4 | 64.0 ± 12.4 |
| 12 to 14 hours | 80.7 ± 17.5 | 71.3 ± 15 | 72.5 ± 13.1 | 73.5 ± 12.6 |
| 14 to 16 hours | 87.7 ± 17.4 | 77.5 ± 15.1 | 79.2 ± 13.2 | 79.7 ± 12.9 |
| 16 to 24 hours | 101.8 ± 17.7 | 92.1 ± 13 | 94.4 ± 15.5 | 95.4 ± 12.0 |
Pharmacodynamics of AZD9977 assessed per urine production for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.
| mL | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| -8 to -2 hours | 321.4 ± 208.3 | 309.3 ± 182.5 | 284.5 ± 186.4 | 294.9 ± 130.3 |
| -2 to 0 hour | 303.5 ± 111.7 | 288.6 ± 99.3 | 274.3 ± 113.7 | 284.5 ± 90.2 |
| 0 to 2 hour | 307.4 ± 78.4 | 320.2 ± 102.6 | 305.0 ± 89.5 | 298.8 ± 68.9 |
| 2 to 4 hour | 272.2 ± 105.0 | 236.1 ± 80.1 | 245.6 ± 63.2 | 272.6 ± 85.8 |
| 4 to 6 hours | 178.8 ± 93.8 | 246.0 ± 115.7 | 229.9 ± 147.7 | 202.2 ± 99.5 |
| 6 to 8 hours | 216.6 ± 99.3 | 115.7 ± 121.6 | 273.6 ± 96.6 | 291.5 ± 135.5 |
| 8 to 10 hours | 266.0 ± 125.4 | 326.6 ± 111.7 | 246.6 ± 103.9 | 300.2 ± 121.1 |
| 10 to 12 hours | 337.1 ± 132.0 | 361.9 ± 149.0 | 309.0 ± 137.4 | 324.5 ± 143.6 |
| 12 to 14 hours | 280.2 ± 131.0 | 300.7 ± 141.8 | 306.0 ± 125.4 | 306.3 ± 152.2 |
| 14 to 16 hours | 357.3 ± 124.8 | 345.9 ± 129.0 | 326.5 ± 115.3 | 354.2 ± 138.6 |
| 16 to 24 hours | 296.0 ± 184.1 | 302.8 ± 181.1 | 292.2 ± 164.8 | 290.6 ± 90.2 |
Pharmacodynamics of AZD9977 by assessment of total urine volume excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone
| mL | Treatment A | Treatment D | Treatment B | Treatment C |
|---|---|---|---|---|
| 0 to 2 hour | 307.4 ± 78.4 | 320.2 ± 102.6 | 305.0 ± 89.5 | 298.8 ± 68.9 |
| 2 to 4 hour | 579.5 ± 127.2 | 556.3 ± 126.1 | 550.7 ± 109.2 | 571.4 ± 128.3 |
| 4 to 6 hours | 758.3 ± 186.3 | 802.2 ± 189.7 | 780.6 ± 204.6 | 773.6 ± 184.1 |
| 6 to 8 hours | 974.9 ± 235.6 | 1099.0 ± 199.1 | 1054.2 ± 201.4 | 1065.1 ± 261.1 |
| 8 to 10 hours | 1242.2 ± 288.9 | 1425.2 ± 235.6 | 1300.8 ± 192.6 | 1365.3 ± 261.1 |
| 10 to 12 hours | 1574.4 ± 329.0 | 1791.7 ± 283.6 | 1609.8 ± 264.2 | 1689.8 ± 300.9 |
| 12 to 14 hours | 1865.1 ± 378.9 | 2091.7 ± 354.6 | 1915.8 ± 264.2 | 1996.1 ± 330.7 |
| 14 to 16 hours | 2221.0 ± 340.7 | 2435.7 ± 304.4 | 2242.3 ± 233.3 | 2350.3 ± 316.6 |
| 16 to 24 hours | 2506.6 ± 388.6 | 2741.2 ± 293.9 | 2534.5 ± 236.3 | 2640.9 ± 347.5 |
Collected over SAEs will be collected from the signing of informed consent and AEs from randomization until post-study 5 to 7 days post-final study drug dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | — | 0/23 (0%) | 2/23 (8.7%) |
| Treatment B | — | 0/23 (0%) | 3/23 (13%) |
| Treatment C | — | 0/23 (0%) | 2/23 (8.7%) |
| Treatment D | — | 0/23 (0%) | 4/23 (17.4%) |
| Event | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/23 | 0/23 | 0/23 | 2/23 |
| DizzinessNervous system disorders | 0/23 | 1/23 | 0/23 | 0/23 |
| Abdominal distentionGastrointestinal disorders | 0/23 | 1/23 | 0/23 | 0/23 |
| Abdominal painGastrointestinal disorders | 0/23 | 0/23 | 1/23 | 0/23 |
| FlatulenceGastrointestinal disorders | 0/23 | 1/23 | 0/23 | 0/23 |
| NasopharyngitisInfections and infestations | 1/23 | 1/23 | 1/23 | 0/23 |
| RhinorrheaRespiratory, thoracic and mediastinal disorders | 0/23 | 0/23 | 0/23 | 1/23 |
| SneezingRespiratory, thoracic and mediastinal disorders | 1/23 | 0/23 | 0/23 | 0/23 |
| Ocular hyperemiaEye disorders | 0/23 | 1/23 | 0/23 | 0/23 |
| PyrexiaGeneral disorders | 0/23 | 0/23 | 0/23 | 1/23 |
| Age, Continuous(years) | All Particpants |
|---|---|
| Mean | 36 ± 8 |
| Sex: Female, Male(Participants) | All Particpants |
|---|---|
| Female | 0 |
| Male | 23 |
The record gives a start of Sep 2015, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD9977